Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3

Yakugaku Zasshi

Volumn 128, Issue 1, 2008, Pages 153-158

  Fujiwara, Kimiko ^a   Tsubaki, Masanobu ^b   Yamazoe, Yuzuru ^a   Nishiura, Saori ^c   Kawaguchi, Takeru ^b   Ogaki, Mitsuhiko ^b   Nishinobo, Minori ^b   Shimamoto, Kenji ^a   Moriyama, Kenzo ^a   Nishida, Shozo ^b  

^a KINDAI UNIVERSITY HOSPITAL   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

Author keywords

Apoptosis; Extracellular signal regulated kinase 1 2; Statin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; TONGUE CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTADIENES; CARCINOMA; CELL LINE, TUMOR; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; NITRILES; PHOSPHORYLATION; POLYISOPRENYL PHOSPHATES; TONGUE NEOPLASMS;

EID: 38149049168     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.153     Document Type: Article

References (13)

1. Chan K. W., Oza A. M., Siu L. L., Clin. Cancer Res., 9, 10-19 (2003).
2. Wong W. W., Dimitroulakos J., Minden M. D., Penn L. Z., Leukemia, 16, 508-519 (2002).
3. Nishida S., Matsuoka H., Tsubaki M., Tanimori Y., Yanae M., Fujii Y., Iwaki M., Mol. Cell. Biochem., 269, 109-114 (2005).
4. Koyuturk M., Ersoz M., Altiok N., Neurosci. Lett., 370, 212-217 (2004).
5. Reszka A. A., Halasy-Nagy J., Rodan G. A., Mol. Pharmacol., 59, 193-202 (2001).
6. Ling S., Wu Y., Zheng J., Linden J., Holoshitz J., Mutat. Res., 554, 33-43 (2004).
7. van de Donk N. W. C. J., Schotte D., Kamphuis M. M. J., van Marion A. M. W., van Kessel B., Bloem A. C., Lokhorst H. M., Clin. Cancer Res., 9, 5735-5748 (2003).
8. Li Y. C., Park M. J., Ye S. K., Kim C. W., Kim Y. N., Am. J. Pathol., 168, 1107-1118 (2006).
9. Paajarvi G., Roudier E., Crisby M., Hogberg J., Stenius U., FASEB J., 19, 476-478 (2004).
10. Scripture C. D., Pieper J.A., Clin. Pharmacokinet., 40, 263-281 (2001).
11. Muck A. O., Seeger H., Wallwiener D., Z. Kardiol., 93, 398-402 (2004).
12. Kubota T., Fujisaki K., Itoh Y., Yano T., Sendo T., Oishi R., Biochem. Pharmacol., 67, 2175-2186 (2004).
13. Kaufmann P., Torok M., Zahno A., Waldhauser K. M., Brecht K., Krahenbuhl S., Cell. Mol. Life Sci., 63, 2415-2425 (2006).